$GH

Kalia Kumud sold $157K of GH

Kalia Kumud (Chief Information Officer) sold 1,200 shares of Guardant Health, Inc. (GH) at an average of $130.97 ($130.86–$131.08, $0.16M total) across 2 trades over 2026-06-10 to 2026-06-15.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 30, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest information is the specific open-market sale details (shares, price range, total value, and post-transaction holdings) filed on 2026-06-30 for trades executed mid-June.

02

Market read

This provides a fresh datapoint on insider behavior, but it is not accompanied by guidance, earnings, or operational developments.

03

What to watch

No 10b5-1 plan is stated; traders may still treat the absence of a plan as marginally more informative, but the disclosed size remains small.

Relevance 4/10Novelty 6/10Timing: Filed after-hours on 2026-06-30; reflects sales executed 2026-06-10 to 2026-06-15.

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc. (GH).

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health CIO Kalia Kumud filed an open-market sale of 1,200 shares at ~$130.97 (total ~$157k) on June 10–15, 2026.

Expected impact

Low likelihood of a sustained price move; any impact would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

This is a Form 4 insider transaction with modest dollar value and no 10b5-1 plan stated; the filing itself is new, but it does not disclose new operating/financial information.

Market effects

Minimal; insider selling at a single healthcare/diagnostics name typically does not reset sector expectations.

None indicated; US-listed Form 4 filing with small transaction value.

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

The sale could be unrelated to company outlook (tax/portfolio rebalancing), especially since the filing does not indicate distress or a planned program.

Key entities

  • Guardant Health, Inc.

    US-listed company whose insider transaction was disclosed via Form 4.

  • Kalia Kumud

    Chief Information Officer who sold 1,200 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

$GHHighAI 9/10

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for advanced HR-positive, HER2-negative breast cancer. This is the first FDA-approved liquid biopsy for longitudinal ctDNA testing in breast cancer. The approval was supported by clinical trial data showing early detection of ESR1 mutations. The company focuses on precision oncology, using blood and tissue tests to tailor cancer treatments. Investors should monitor the impact on future reve

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.